25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Cabio Biotech Wuhan Co Ltd
Buy, Hold or Sell?

Let's analyze Cabio together

I guess you are interested in Cabio Biotech Wuhan Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cabio Biotech Wuhan Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cabio Biotech Wuhan Co Ltd

I send you an email if I find something interesting about Cabio Biotech Wuhan Co Ltd.

1. Quick Overview

1.1. Quick analysis of Cabio (30 sec.)










1.2. What can you expect buying and holding a share of Cabio? (30 sec.)

How much money do you get?

How much money do you get?
¥0.03
When do you have the money?
1 year
How often do you get paid?
45.5%

What is your share worth?

Current worth
¥9.16
Expected worth in 1 year
¥9.59
How sure are you?
77.3%

+ What do you gain per year?

Total Gains per Share
¥0.63
Return On Investment
2.7%

For what price can you sell your share?

Current Price per Share
¥23.20
Expected price per share
¥16.38 - ¥30.12
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cabio (5 min.)




Live pricePrice per Share (EOD)
¥23.20
Intrinsic Value Per Share
¥-16.95 - ¥-20.10
Total Value Per Share
¥-7.79 - ¥-10.94

2.2. Growth of Cabio (5 min.)




Is Cabio growing?

Current yearPrevious yearGrowGrow %
How rich?$211.6m$198.1m$10.4m5.0%

How much money is Cabio making?

Current yearPrevious yearGrowGrow %
Making money$3.9m$1.6m$2.3m59.1%
Net Profit Margin22.4%11.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Cabio (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cabio?

Welcome investor! Cabio's management wants to use your money to grow the business. In return you get a share of Cabio.

First you should know what it really means to hold a share of Cabio. And how you can make/lose money.

Speculation

The Price per Share of Cabio is ¥23.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cabio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cabio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥9.16. Based on the TTM, the Book Value Change Per Share is ¥0.11 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cabio.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.1%0.020.1%0.010.0%0.020.1%0.020.1%
Usd Book Value Change Per Share0.010.1%0.010.1%0.010.0%0.040.2%0.060.2%
Usd Dividend Per Share0.000.0%0.010.0%0.010.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.1%0.020.1%0.020.1%0.040.2%0.060.3%
Usd Price Per Share2.79-2.26-4.59-4.98-4.53-
Price to Earnings Ratio53.36-28.89-16.74-47.06-42.78-
Price-to-Total Gains Ratio228.16-126.50--591.53--68.81--68.81-
Price to Book Ratio2.22-1.82-3.91-4.47-4.06-
Price-to-Total Gains Ratio228.16-126.50--591.53--68.81--68.81-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.18536
Number of shares313
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share0.010.04
Usd Total Gains Per Share0.020.04
Gains per Quarter (313 shares)6.7613.71
Gains per Year (313 shares)27.0454.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
19181764945
21737441198100
326557117148155
435739823197210
5439212528246265
65211015234295320
76112817940344375
87014720645393430
97816523351443485
108718426056492540

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%21.01.00.095.5%21.01.00.095.5%
Book Value Change Per Share4.00.00.0100.0%9.03.00.075.0%15.05.00.075.0%17.05.00.077.3%17.05.00.077.3%
Dividend per Share4.00.00.0100.0%10.00.02.083.3%10.00.010.050.0%10.00.012.045.5%10.00.012.045.5%
Total Gains per Share4.00.00.0100.0%9.03.00.075.0%15.05.00.075.0%17.05.00.077.3%17.05.00.077.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cabio Biotech Wuhan Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0880.107-17%0.058+52%0.286-69%0.416-79%
Book Value Per Share--9.1589.030+1%8.576+7%8.291+10%7.840+17%
Current Ratio--6.2246.642-6%6.533-5%14.076-56%13.735-55%
Debt To Asset Ratio--0.0740.069+7%0.087-15%0.062+19%0.064+16%
Debt To Equity Ratio--0.0810.075+7%0.096-16%0.068+19%0.069+17%
Dividend Per Share--0.0010.051-99%0.055-99%0.033-98%0.030-98%
Enterprise Value--3291802099.0002660550062.983+24%5492791331.317-40%6015669872.774-45%6015669872.774-45%
Eps--0.0950.171-44%0.070+36%0.155-39%0.161-41%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--6.5155.319+22%11.828-45%16.316-60%16.316-60%
Free Cash Flow Per Share---0.505-0.133-74%-0.265-48%-0.075-85%-0.069-86%
Free Cash Flow To Equity Per Share---0.505-0.133-74%-0.294-42%-0.098-81%-0.091-82%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---20.103--------
Intrinsic Value_10Y_min---16.953--------
Intrinsic Value_1Y_max---0.922--------
Intrinsic Value_1Y_min---0.905--------
Intrinsic Value_3Y_max---3.603--------
Intrinsic Value_3Y_min---3.423--------
Intrinsic Value_5Y_max---7.287--------
Intrinsic Value_5Y_min---6.692--------
Market Cap3904768614.400+13%3414992044.8002773734297.600+23%5630362342.445-39%6110544530.002-44%5555040481.820-39%
Net Profit Margin--0.1270.224-44%0.117+9%0.281-55%0.296-57%
Operating Margin----0%0.079-100%0.144-100%0.181-100%
Operating Ratio--1.5271.363+12%1.410+8%1.278+19%1.260+21%
Pb Ratio2.533+13%2.2161.825+21%3.913-43%4.466-50%4.060-45%
Pe Ratio61.007+13%53.35528.886+85%16.744+219%47.059+13%42.781+25%
Price Per Share23.200+13%20.29016.480+23%33.453-39%36.306-44%33.005-39%
Price To Free Cash Flow Ratio-11.491-14%-10.050-22.416+123%41.106-124%6.655-251%6.050-266%
Price To Total Gains Ratio260.885+13%228.162126.503+80%-591.528+359%-68.808+130%-68.808+130%
Quick Ratio--2.8602.638+8%2.241+28%4.699-39%4.501-36%
Return On Assets--0.0100.018-45%0.008+27%0.018-46%0.022-56%
Return On Equity--0.0100.019-45%0.008+30%0.019-45%0.023-55%
Total Gains Per Share--0.0890.157-43%0.112-21%0.319-72%0.446-80%
Usd Book Value--211634709.421208675445.587+1%198188460.232+7%191593323.366+10%181184361.182+17%
Usd Book Value Change Per Share--0.0120.015-17%0.008+52%0.039-69%0.057-79%
Usd Book Value Per Share--1.2571.240+1%1.178+7%1.138+10%1.076+17%
Usd Dividend Per Share--0.0000.007-99%0.007-99%0.005-98%0.004-98%
Usd Enterprise Value--451964428.193365293523.647+24%754160249.790-40%825951473.532-45%825951473.532-45%
Usd Eps--0.0130.023-44%0.010+36%0.021-39%0.022-41%
Usd Free Cash Flow---11663652.849-3064704.076-74%-6120707.476-48%-1739854.215-85%-1526334.507-87%
Usd Free Cash Flow Per Share---0.069-0.018-74%-0.036-48%-0.010-85%-0.010-86%
Usd Free Cash Flow To Equity Per Share---0.069-0.018-74%-0.040-42%-0.014-81%-0.013-82%
Usd Market Cap536124730.757+13%468878407.751380833719.060+23%773048749.618-39%838977763.969-44%762707058.154-39%
Usd Price Per Share3.185+13%2.7862.263+23%4.593-39%4.985-44%4.532-39%
Usd Profit--2196967.7863942229.427-44%1610577.535+36%3576469.181-39%3711536.397-41%
Usd Revenue--17343119.52717372656.9170%16647916.005+4%13862567.808+25%13632547.347+27%
Usd Total Gains Per Share--0.0120.022-43%0.015-21%0.044-72%0.061-80%
 EOD+5 -3MRQTTM+11 -26YOY+19 -195Y+8 -3010Y+8 -30

3.3 Fundamental Score

Let's check the fundamental score of Cabio Biotech Wuhan Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1561.007
Price to Book Ratio (EOD)Between0-12.533
Net Profit Margin (MRQ)Greater than00.127
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.860
Current Ratio (MRQ)Greater than16.224
Debt to Asset Ratio (MRQ)Less than10.074
Debt to Equity Ratio (MRQ)Less than10.081
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.010
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Cabio Biotech Wuhan Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.033
Ma 20Greater thanMa 5022.366
Ma 50Greater thanMa 10020.443
Ma 100Greater thanMa 20020.773
OpenGreater thanClose22.870
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Cabio Biotech Wuhan Co Ltd

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.

Fundamental data was last updated by Penke on 2025-02-23 11:21:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Cabio earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Cabio to the Biotechnology industry mean.
  • A Net Profit Margin of 12.7% means that ¥0.13 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 12.7%. The company is making a huge profit. +2
  • The TTM is 22.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ12.7%TTM22.4%-9.8%
TTM22.4%YOY11.7%+10.8%
TTM22.4%5Y28.1%-5.6%
5Y28.1%10Y29.6%-1.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.7%-101.0%+113.7%
TTM22.4%-203.6%+226.0%
YOY11.7%-199.0%+210.7%
5Y28.1%-333.8%+361.9%
10Y29.6%-481.5%+511.1%
4.3.1.2. Return on Assets

Shows how efficient Cabio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cabio to the Biotechnology industry mean.
  • 1.0% Return on Assets means that Cabio generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 1.0%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.8%-0.8%
TTM1.8%YOY0.8%+1.0%
TTM1.8%5Y1.8%0.0%
5Y1.8%10Y2.2%-0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-12.4%+13.4%
TTM1.8%-12.4%+14.2%
YOY0.8%-11.8%+12.6%
5Y1.8%-13.2%+15.0%
10Y2.2%-15.2%+17.4%
4.3.1.3. Return on Equity

Shows how efficient Cabio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cabio to the Biotechnology industry mean.
  • 1.0% Return on Equity means Cabio generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.9%-0.9%
TTM1.9%YOY0.8%+1.1%
TTM1.9%5Y1.9%+0.0%
5Y1.9%10Y2.3%-0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-15.9%+16.9%
TTM1.9%-16.6%+18.5%
YOY0.8%-15.2%+16.0%
5Y1.9%-19.0%+20.9%
10Y2.3%-20.5%+22.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cabio Biotech Wuhan Co Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Cabio is operating .

  • Measures how much profit Cabio makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cabio to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY7.9%-7.9%
TTM-5Y14.4%-14.4%
5Y14.4%10Y18.1%-3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.6%+204.6%
TTM--316.3%+316.3%
YOY7.9%-208.2%+216.1%
5Y14.4%-367.6%+382.0%
10Y18.1%-483.9%+502.0%
4.3.2.2. Operating Ratio

Measures how efficient Cabio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.53 means that the operating costs are ¥1.53 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 1.527. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.363. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.527TTM1.363+0.164
TTM1.363YOY1.410-0.048
TTM1.3635Y1.278+0.085
5Y1.27810Y1.260+0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5272.167-0.640
TTM1.3633.118-1.755
YOY1.4103.194-1.784
5Y1.2784.689-3.411
10Y1.2606.422-5.162
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cabio Biotech Wuhan Co Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cabio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.22 means the company has ¥6.22 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 6.224. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.642. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.224TTM6.642-0.418
TTM6.642YOY6.533+0.109
TTM6.6425Y14.076-7.434
5Y14.07610Y13.735+0.341
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2243.586+2.638
TTM6.6423.854+2.788
YOY6.5334.496+2.037
5Y14.0765.971+8.105
10Y13.7356.269+7.466
4.4.3.2. Quick Ratio

Measures if Cabio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cabio to the Biotechnology industry mean.
  • A Quick Ratio of 2.86 means the company can pay off ¥2.86 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 2.860. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.638. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.860TTM2.638+0.221
TTM2.638YOY2.241+0.397
TTM2.6385Y4.699-2.061
5Y4.69910Y4.501+0.198
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8603.068-0.208
TTM2.6383.312-0.674
YOY2.2414.393-2.152
5Y4.6995.972-1.273
10Y4.5016.490-1.989
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cabio Biotech Wuhan Co Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Cabio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cabio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07 means that Cabio assets are financed with 7.4% credit (debt) and the remaining percentage (100% - 7.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 0.074. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.069. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.074TTM0.069+0.005
TTM0.069YOY0.087-0.017
TTM0.0695Y0.062+0.007
5Y0.06210Y0.064-0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0740.340-0.266
TTM0.0690.341-0.272
YOY0.0870.310-0.223
5Y0.0620.363-0.301
10Y0.0640.384-0.320
4.5.4.2. Debt to Equity Ratio

Measures if Cabio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cabio to the Biotechnology industry mean.
  • A Debt to Equity ratio of 8.1% means that company has ¥0.08 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cabio Biotech Wuhan Co Ltd:

  • The MRQ is 0.081. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.075. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.081TTM0.075+0.005
TTM0.075YOY0.096-0.021
TTM0.0755Y0.068+0.008
5Y0.06810Y0.069-0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0810.387-0.306
TTM0.0750.428-0.353
YOY0.0960.391-0.295
5Y0.0680.451-0.383
10Y0.0690.495-0.426
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Cabio generates.

  • Above 15 is considered overpriced but always compare Cabio to the Biotechnology industry mean.
  • A PE ratio of 53.36 means the investor is paying ¥53.36 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cabio Biotech Wuhan Co Ltd:

  • The EOD is 61.007. Based on the earnings, the company is expensive. -2
  • The MRQ is 53.355. Based on the earnings, the company is expensive. -2
  • The TTM is 28.886. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD61.007MRQ53.355+7.652
MRQ53.355TTM28.886+24.469
TTM28.886YOY16.744+12.142
TTM28.8865Y47.059-18.173
5Y47.05910Y42.781+4.278
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD61.007-2.225+63.232
MRQ53.355-2.782+56.137
TTM28.886-3.265+32.151
YOY16.744-3.409+20.153
5Y47.059-6.283+53.342
10Y42.781-6.819+49.600
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cabio Biotech Wuhan Co Ltd:

  • The EOD is -11.491. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.050. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -22.416. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.491MRQ-10.050-1.441
MRQ-10.050TTM-22.416+12.366
TTM-22.416YOY41.106-63.522
TTM-22.4165Y6.655-29.071
5Y6.65510Y6.050+0.605
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.491-3.016-8.475
MRQ-10.050-3.724-6.326
TTM-22.416-3.891-18.525
YOY41.106-4.438+45.544
5Y6.655-8.306+14.961
10Y6.050-9.270+15.320
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Cabio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.22 means the investor is paying ¥2.22 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Cabio Biotech Wuhan Co Ltd:

  • The EOD is 2.533. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.216. Based on the equity, the company is underpriced. +1
  • The TTM is 1.825. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.533MRQ2.216+0.318
MRQ2.216TTM1.825+0.391
TTM1.825YOY3.913-2.088
TTM1.8255Y4.466-2.641
5Y4.46610Y4.060+0.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.5331.915+0.618
MRQ2.2162.191+0.025
TTM1.8252.397-0.572
YOY3.9132.465+1.448
5Y4.4663.815+0.651
10Y4.0604.512-0.452
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets1,664,594
Total Liabilities123,190
Total Stockholder Equity1,526,593
 As reported
Total Liabilities 123,190
Total Stockholder Equity+ 1,526,593
Total Assets = 1,664,594

Assets

Total Assets1,664,594
Total Current Assets672,289
Long-term Assets992,305
Total Current Assets
Cash And Cash Equivalents 105,606
Short-term Investments 53,031
Net Receivables 255,875
Inventory 131,204
Other Current Assets 56,582
Total Current Assets  (as reported)672,289
Total Current Assets  (calculated)602,299
+/- 69,990
Long-term Assets
Property Plant Equipment 743,404
Intangible Assets 42,654
Long-term Assets Other 11,697
Long-term Assets  (as reported)992,305
Long-term Assets  (calculated)797,755
+/- 194,550

Liabilities & Shareholders' Equity

Total Current Liabilities108,024
Long-term Liabilities15,166
Total Stockholder Equity1,526,593
Total Current Liabilities
Short Long Term Debt 6,001
Accounts payable 79,897
Other Current Liabilities 96
Total Current Liabilities  (as reported)108,024
Total Current Liabilities  (calculated)85,993
+/- 22,031
Long-term Liabilities
Long term Debt 11,186
Capital Lease Obligations Min Short Term Debt346
Long-term Liabilities  (as reported)15,166
Long-term Liabilities  (calculated)11,532
+/- 3,634
Total Stockholder Equity
Retained Earnings 471,570
Total Stockholder Equity (as reported)1,526,593
Total Stockholder Equity (calculated)471,570
+/- 1,055,023
Other
Capital Stock168,309
Common Stock Shares Outstanding 168,309
Net Invested Capital 1,543,780
Net Working Capital 564,265
Property Plant and Equipment Gross 743,404



6.2. Balance Sheets Structured

Currency in CNY. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-30
> Total Assets 
588,538
626,553
1,297,832
1,319,807
1,368,303
1,347,693
1,382,821
1,396,974
1,402,502
1,409,391
1,448,491
1,470,211
1,564,121
1,541,759
1,610,828
1,592,110
1,565,469
1,555,758
1,611,493
1,617,239
1,638,813
1,664,594
1,664,5941,638,8131,617,2391,611,4931,555,7581,565,4691,592,1101,610,8281,541,7591,564,1211,470,2111,448,4911,409,3911,402,5021,396,9741,382,8211,347,6931,368,3031,319,8071,297,832626,553588,538
   > Total Current Assets 
389,579
428,781
1,099,063
1,128,137
1,173,454
1,098,717
1,123,140
1,131,760
1,120,522
1,022,581
994,851
914,551
947,139
879,054
907,366
834,777
787,916
730,942
708,778
695,345
703,614
672,289
672,289703,614695,345708,778730,942787,916834,777907,366879,054947,139914,551994,8511,022,5811,120,5221,131,7601,123,1401,098,7171,173,4541,128,1371,099,063428,781389,579
       Cash And Cash Equivalents 
124,069
142,410
844,319
899,213
369,106
328,631
847,316
282,584
625,562
367,240
664,468
537,873
456,243
386,593
494,327
380,072
321,317
236,255
239,677
191,773
203,074
105,606
105,606203,074191,773239,677236,255321,317380,072494,327386,593456,243537,873664,468367,240625,562282,584847,316328,631369,106899,213844,319142,410124,069
       Short-term Investments 
0
0
0
0
554,000
506,000
13,520
543,948
200,093
330,482
11,499
101,593
180,000
145,866
32,800
60,030
61,421
40,030
31
40,031
46,031
53,031
53,03146,03140,0313140,03061,42160,03032,800145,866180,000101,59311,499330,482200,093543,94813,520506,000554,0000000
       Net Receivables 
86,153
113,793
110,158
103,123
104,080
116,687
128,502
135,444
148,773
169,865
151,078
122,112
131,886
221,112
256,988
210,242
235,110
212,137
214,813
244,207
246,065
255,875
255,875246,065244,207214,813212,137235,110210,242256,988221,112131,886122,112151,078169,865148,773135,444128,502116,687104,080103,123110,158113,79386,153
       Inventory 
74,957
78,963
65,857
63,601
62,014
68,400
65,477
76,808
77,119
76,516
74,856
75,259
78,216
83,980
81,491
115,581
124,641
116,182
112,578
107,449
107,676
131,204
131,204107,676107,449112,578116,182124,641115,58181,49183,98078,21675,25974,85676,51677,11976,80865,47768,40062,01463,60165,85778,96374,957
       Other Current Assets 
16,614
15,549
15,922
19,285
17,568
18,778
17,720
20,539
18,163
19,660
23,329
21,503
25,083
41,504
41,759
68,852
45,427
48,353
51,281
53,002
49,570
56,582
56,58249,57053,00251,28148,35345,42768,85241,75941,50425,08321,50323,32919,66018,16320,53917,72018,77817,56819,28515,92215,54916,614
   > Long-term Assets 
198,959
197,772
198,769
191,670
194,848
248,976
259,681
265,214
281,980
386,811
453,640
555,661
616,982
662,705
703,462
757,332
777,553
824,816
902,715
921,894
935,198
992,305
992,305935,198921,894902,715824,816777,553757,332703,462662,705616,982555,661453,640386,811281,980265,214259,681248,976194,848191,670198,769197,772198,959
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
347,321
485,961
517,809
534,050
572,052
643,275
666,383
681,316
743,404
743,404681,316666,383643,275572,052534,050517,809485,961347,3210000000000000
       Intangible Assets 
2,497
14,685
14,302
14,040
14,871
14,482
14,539
14,134
13,739
13,355
13,155
13,097
29,925
29,561
36,338
36,442
36,427
36,004
41,083
42,204
41,976
42,654
42,65441,97642,20441,08336,00436,42736,44236,33829,56129,92513,09713,15513,35513,73914,13414,53914,48214,87114,04014,30214,6852,497
       Long-term Assets Other 
2,375
1,661
6,016
2,544
6,887
161,483
23,587
31,347
43,914
74,010
74,892
106,724
78,935
97,742
17,517
17,618
17,685
27,361
28,183
24,327
23,852
11,697
11,69723,85224,32728,18327,36117,68517,61817,51797,74278,935106,72474,89274,01043,91431,34723,587161,4836,8872,5446,0161,6612,375
> Total Liabilities 
43,882
48,197
48,256
43,874
104,705
44,522
59,301
49,521
82,692
54,877
66,677
62,511
166,312
111,225
185,768
150,554
127,732
86,231
117,601
99,674
112,271
123,190
123,190112,27199,674117,60186,231127,732150,554185,768111,225166,31262,51166,67754,87782,69249,52159,30144,522104,70543,87448,25648,19743,882
   > Total Current Liabilities 
38,971
40,270
41,697
37,606
98,724
37,817
52,320
42,487
76,448
47,697
59,954
55,898
160,072
103,912
180,443
144,843
123,509
81,582
112,423
95,051
104,638
108,024
108,024104,63895,051112,42381,582123,509144,843180,443103,912160,07255,89859,95447,69776,44842,48752,32037,81798,72437,60641,69740,27038,971
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
835
81
54
0
31,381
35,034
5,995
10,009
11,011
11,008
11,007
6,001
6,00111,00711,00811,01110,0095,99535,03431,381054818350000000000
       Accounts payable 
14,555
12,674
18,784
21,084
17,650
17,581
24,531
25,083
19,267
24,424
31,427
36,472
43,108
37,734
107,335
86,225
62,991
45,926
70,859
63,970
70,107
79,897
79,89770,10763,97070,85945,92662,99186,225107,33537,73443,10836,47231,42724,42419,26725,08324,53117,58117,65021,08418,78412,67414,555
       Other Current Liabilities 
0
0
0
483
0
0
117
18
18
49
30
72
70
53,817
22,573
5,532
43,709
69
271
93
45
96
9645932716943,7095,53222,57353,81770723049181811700483000
   > Long-term Liabilities 
4,911
7,927
6,559
6,268
5,981
6,705
6,981
7,034
6,244
7,180
6,723
6,613
6,239
7,312
5,325
5,710
4,223
4,649
5,178
4,623
7,633
15,166
15,1667,6334,6235,1784,6494,2235,7105,3257,3126,2396,6136,7237,1806,2447,0346,9816,7055,9816,2686,5597,9274,911
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
5,390
3,660
3,203
3,154
0
0
0
0
0
000003,1543,2033,6605,3900000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,285
0
0
4,570
0
0
0
0
0
000004,570002,2850000000000000
> Total Stockholder Equity
544,838
577,938
1,248,340
1,273,889
1,260,025
1,298,199
1,317,931
1,342,471
1,319,810
1,353,209
1,381,024
1,406,162
1,397,030
1,428,729
1,418,953
1,436,185
1,429,135
1,457,602
1,476,353
1,500,664
1,510,569
1,526,593
1,526,5931,510,5691,500,6641,476,3531,457,6021,429,1351,436,1851,418,9531,428,7291,397,0301,406,1621,381,0241,353,2091,319,8101,342,4711,317,9311,298,1991,260,0251,273,8891,248,340577,938544,838
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
120,000
120,000
120,000
120,221
0
0
0
0
0
00000120,221120,000120,000120,0000000000000000
   Retained Earnings 
173,723
206,431
223,355
248,713
234,565
273,462
281,444
315,199
309,411
342,792
359,749
382,974
370,173
455,162
375,377
455,976
440,450
396,478
421,341
445,654
448,637
471,570
471,570448,637445,654421,341396,478440,450455,976375,377455,162370,173382,974359,749342,792309,411315,199281,444273,462234,565248,713223,355206,431173,723
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
-714
-732
860,209
-749
0
0
0
0
0
00000-749860,209-732-7140000000000000



6.3. Balance Sheets

Currency in CNY. All numbers in thousands.




6.4. Cash Flows

Currency in CNY. All numbers in thousands.




6.5. Income Statements

Currency in CNY. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in CNY. All numbers in thousands.

Gross Profit (+$)
totalRevenue443,803
Cost of Revenue-255,642
Gross Profit188,161188,161
 
Operating Income (+$)
Gross Profit188,161
Operating Expense-351,803
Operating Income92,000-163,642
 
Operating Expense (+$)
Research Development38,597
Selling General Administrative27,297
Selling And Marketing Expenses0
Operating Expense351,80365,894
 
Net Interest Income (+$)
Interest Income2,088
Interest Expense-595
Other Finance Cost-170
Net Interest Income1,323
 
Pretax Income (+$)
Operating Income92,000
Net Interest Income1,323
Other Non-Operating Income Expenses0
Income Before Tax (EBT)100,00292,000
EBIT - interestExpense = -595
91,374
91,970
Interest Expense595
Earnings Before Interest and Taxes (EBIT)0100,597
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax100,002
Tax Provision-13,634
Net Income From Continuing Ops86,36786,367
Net Income91,374
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-1,323
 

Technical Analysis of Cabio
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cabio. The general trend of Cabio is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cabio's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cabio Biotech Wuhan Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 26.89 < 29.34 < 30.12.

The bearish price targets are: 17.32 > 16.93 > 16.38.

Tweet this
Cabio Biotech Wuhan Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cabio Biotech Wuhan Co Ltd. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cabio Biotech Wuhan Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cabio Biotech Wuhan Co Ltd. The current macd is 0.8233604.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cabio price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cabio. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cabio price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cabio Biotech Wuhan Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartCabio Biotech Wuhan Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cabio Biotech Wuhan Co Ltd. The current adx is 36.83.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cabio shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Cabio Biotech Wuhan Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cabio Biotech Wuhan Co Ltd. The current sar is 26.06.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cabio Biotech Wuhan Co Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cabio Biotech Wuhan Co Ltd. The current rsi is 59.03. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Cabio Biotech Wuhan Co Ltd Daily Relative Strength Index (RSI) ChartCabio Biotech Wuhan Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cabio Biotech Wuhan Co Ltd. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cabio price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cabio Biotech Wuhan Co Ltd Daily Stochastic Oscillator ChartCabio Biotech Wuhan Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cabio Biotech Wuhan Co Ltd. The current cci is 52.66.

Cabio Biotech Wuhan Co Ltd Daily Commodity Channel Index (CCI) ChartCabio Biotech Wuhan Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cabio Biotech Wuhan Co Ltd. The current cmo is 17.55.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cabio Biotech Wuhan Co Ltd Daily Chande Momentum Oscillator (CMO) ChartCabio Biotech Wuhan Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cabio Biotech Wuhan Co Ltd. The current willr is -68.84328358.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cabio is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cabio Biotech Wuhan Co Ltd Daily Williams %R ChartCabio Biotech Wuhan Co Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cabio Biotech Wuhan Co Ltd.

Cabio Biotech Wuhan Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cabio Biotech Wuhan Co Ltd. The current atr is 1.0721611.

Cabio Biotech Wuhan Co Ltd Daily Average True Range (ATR) ChartCabio Biotech Wuhan Co Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cabio Biotech Wuhan Co Ltd. The current obv is 37,402,416.

Cabio Biotech Wuhan Co Ltd Daily On-Balance Volume (OBV) ChartCabio Biotech Wuhan Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cabio Biotech Wuhan Co Ltd. The current mfi is 62.50.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cabio Biotech Wuhan Co Ltd Daily Money Flow Index (MFI) ChartCabio Biotech Wuhan Co Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cabio Biotech Wuhan Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-03ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-10BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-17STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Cabio Biotech Wuhan Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cabio Biotech Wuhan Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.033
Ma 20Greater thanMa 5022.366
Ma 50Greater thanMa 10020.443
Ma 100Greater thanMa 20020.773
OpenGreater thanClose22.870
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cabio with someone you think should read this too:
  • Are you bullish or bearish on Cabio? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cabio? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cabio Biotech Wuhan Co Ltd

I send you an email if I find something interesting about Cabio Biotech Wuhan Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Cabio Biotech Wuhan Co Ltd.

Receive notifications about Cabio Biotech Wuhan Co Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.